Vertical transmission from mother to child is the main mode of transmission of hepatitis B virus (HBV) infection in China, China’s hepatitis B virus infection in the reproductive age of up to 8.16% of the population, how to keep our next generation away from hepatitis B, scientific and standardized mother-to-child interruption measures are particularly important. 1.Mother-to-child transmission of HBV: infection in utero, infection during childbirth, and infection in close contact after delivery. 2, risk factors for mother-to-child transmission: high viral (HBV-DNA) load and maternal preterm labor during pregnancy are risk factors for in utero infection, and there is no significant correlation between the mode of delivery (natural birth/caesarean section/perineal lateralization) and the risk of mother-to-child transmission. 3. Measures to block mother-to-child transmission of HBV: The 2010 edition of the Chinese Guidelines for the Prevention and Control of Hepatitis B states that newborns of HBsAg-positive mothers should be given hepatitis B immunoglobulin (HBIG) at a dose of ≥100 IU as early as possible within 24 h after birth (preferably 12 h after birth), along with 10 μg recombinant yeast or 20 μg Chinese hamster oocyte ( CHO) hepatitis B vaccine at 1 and 6 months of age, and the 2nd and 3rd doses of hepatitis B vaccine at 1 and 6 months of age, respectively; or 1 dose of HBIG within 12 h after birth, followed by the 2nd dose of HBIG 1 month later, and a 10 μg recombinant yeast or 20 μg CHO hepatitis B vaccine at different sites at the same time, and the 2nd and 3rd doses of hepatitis B vaccine at 1 and 6 months of age, respectively The newborns can receive breastfeeding from HBsAg-positive mothers after HBIG and hepatitis B vaccine are administered within 12 hours of birth. The vaccination site for newborns is within the lateral muscle of the anterior gluteal region. 4, antiviral therapy for high viral load carriers at the end of pregnancy: some data show that maternal serum HBV-DNA > 108copies/ml, the newborn was born even with standard combined immunoprophylaxis, the mother-to-child transmission rate is still as high as 8.5%, currently some scholars recommend that for high viral load carriers, the application of pregnancy B drugs lamivudine, telbivudine, and tenofovir starting at 32 weeks of gestation. Tenofovir treatment can reduce HBV infection in utero, but evidence of treatment benefit versus risk is insufficient. Women of childbearing age should be extensively screened for HBsAg, and those who are HBsAg negative but at high risk for HBV infection (multiple sexual partners, intravenous drug addicts, and those whose sexual partners are HBsAg positive) should be standardized for vaccination; vaccination is safe during pregnancy and should be standardized for infants at birth.